| In response to difficulties prescribing anti-tumour drugs after their inclusion in health insurance, and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, will raise these concerns with regulators in coordination with the media. | Cancro
> Cancro: la maggior parte dei tipi | Partenariato normativo
> Collaborazione con gli organismi di regolamentazione | 100.000 | National | Sometimes | 114998326269 |
| We submit surveys/proposals to CFDA [China Food and Drug Administration] and CDE [Center for Drug Evaluation]. | Respiratorio
> Ipertensione polmonare | Partenariato normativo
> Collaborazione con gli organismi di regolamentazione | 10.000 | National | Regularly | 115007302730 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | Salute generale
> Salute pubblica | Partenariato normativo
> Contribuire alle presentazioni per l'Autorizzazione all'Immissione in Commercio | 100.000 | National | Sometimes | 115023378250 |
| I have received an invitation from the CDE [药品审评中心 – Center for Drug Evaluation] to participate in a closed-door meeting. | Cancro
> Cancro: sangue | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 100.000 | National | Rarely | 115007439380 |
| Roundtable discussions are primarily convened by invitation from the NMPA [National Medical Products Administration]. | Cancro
> Cancro: sangue | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 100.000 | National | Rarely | 115008256034 |
| Communicating and raising concerns with the NHSA [国家医疗保障局 – National Healthcare Security Administration/China]. | Raro
> Malattia di Fabry | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 1000 | National | Regularly | 115013642356 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancro
> Cancro: la maggior parte dei tipi | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 100.000 | National | Sometimes | 115033327817 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Raro
> Malattie rare: la maggior parte dei tipi | Partenariato normativo
> Partecipare/facilitare riunioni con responsabili politici/regolatori | 5000 | National | Rarely | 115063429838 |
| Submitting advocacy letters to regulatory authorities. | Raro
> Malattie rare: la maggior parte dei tipi | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 1000 | National | Regularly | 115029711188 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Fegato
> Epatite | Influenzare le politiche e la legislazione
> Influenzare le politiche sanitarie e la legislazione | 100.000 | National | Regularly | 115050575369 |
| Proposals submitted to the Lianghui [两会 – the annual plenary sessions of China's National People's Congress and the Chinese People's Political Consultative Conference]. | Salute generale
> Salute pubblica | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | 100.000 | National | Regularly | 115023383007 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | Raro
> Malattie rare: la maggior parte dei tipi | Influenzare le politiche e la legislazione
> Partecipa alle audizioni pubbliche e alle consultazioni | 5000 | National | Rarely | 115063429838 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancro
> Cancro: la maggior parte dei tipi | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 100.000 | National | Sometimes | 115030437530 |
| Patient-facing media advocacy content relating to healthcare insurance coverage. | Cancro
> Cancro: la maggior parte dei tipi | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 100.000 | National | Sometimes | 115032740364 |
| We raise our voice on the issue of drug pricing. | Endocrino
> Diabete: tipo 2 | Advocacy per prezzi e accessibilità economica
> Sostenere prezzi equi dei farmaci | 10.000 | Regional | Rarely | 115051912364 |
| In our capacity as the initiating organization of a Patient Assistance Program (PAP) for newly approved medicines, we gather and represent patient perspectives. Where a genuine unmet clinical need exists and no clinically viable alternative is available in China, we advocate for the regulatory approval and market authorization of therapies such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy], while providing evidence on the financial burden borne by patients. | Salute generale
> Salute pubblica | Advocacy per prezzi e accessibilità economica
> Affrontare le barriere di costo per le persone a basso reddito e vulnerabili | 100.000 | National | Sometimes | 115023378250 |
| In response to difficulties prescribing anti-tumour drugs after their inclusion in the NRDL [ 国家医保药品目录 - China's National Reimbursement Drug List], and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, we will raise these concerns with regulators in coordination with the media. | Cancro
> Cancro: la maggior parte dei tipi | Advocacy per prezzi e accessibilità economica
> Monitoraggio e tracciamento dei prezzi dei farmaci/carenze di farmaci | 100.000 | National | Sometimes | 114998326269 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancro
> Cancro: la maggior parte dei tipi | Advocacy per prezzi e accessibilità economica
> Monitoraggio e tracciamento dei prezzi dei farmaci/carenze di farmaci | 100.000 | National | Sometimes | 115030437530 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Neurologico
> Sclerosi multipla | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 10.000 | National | Sometimes | 115000464773 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | Neurologico
> Sclerosi multipla | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 10.000 | National | Sometimes | 115000464773 |
| I will advocate on issues relating to pharmaceutical pricing and the inclusion of pharmaceutical products and medical devices in the national medical insurance (NMI) reimbursement market. | Endocrino
> Diabete: tipo 2 | Advocacy per prezzi e accessibilità economica
> Sostenere l'inclusione del prodotto negli elenchi di rimborso/formulari nazionali | 10.000 | Regional | Rarely | 115051912364 |
| Patient-facing media advocacy content relating to healthcare insurance coverage [in China]. | Cancro
> Cancro: la maggior parte dei tipi | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 100.000 | National | Sometimes | 115032740364 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Cancro
> Cancro: la maggior parte dei tipi | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 100.000 | National | Rarely | 115037193619 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Reumatico
> Lupus | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 100.000 | National | Sometimes | 115046738886 |
| Policy advocacy and healthcare access support constitute the core areas of business. | Fegato
> Epatite | Miglioramento dei percorsi di accesso
> Facilitare l'accesso equo ai medicinali/all'assistenza sanitaria | 100.000 | National | Regularly | 115050575369 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | Reumatico
> Lupus | Miglioramento dei percorsi di accesso
> Affrontare le disparità nell'accesso e nella gestione | 100.000 | National | Sometimes | 115046738886 |
| Patient needs and concerns should be communicated to policy-making bodies such as the National Healthcare Security Administration [国家医疗保障局 – China's national authority responsible for healthcare security and reimbursement policy]. | Pelle
> Condizioni della pelle: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 100.000 | National | Sometimes | 115007238824 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | Salute generale
> Salute pubblica | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 100.000 | National | Sometimes | 115023378250 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancro
> Cancro: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Utilizza le informazioni sui pazienti per prendere decisioni informate | 100.000 | National | Sometimes | 115033327817 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | Cancro
> Cancro: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Sfrutta le storie dei pazienti e le narrazioni basate sull'esperienza vissuta | 100.000 | National | Rarely | 115037193619 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | Cancro
> Cancro: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Condurre sondaggi/ricerche per generare dati | 100.000 | National | Sometimes | 115030437530 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | Cancro
> Cancro: la maggior parte dei tipi | Contributo del paziente basato sull'evidenza
> Condurre sondaggi/ricerche per generare dati | 100.000 | National | Sometimes | 115033327817 |
interazioni
azioni e advocacy
8 menzioni
